NCT04602169 (RECONNECT) is a NA clinical trial of PVI in Paroxysmal Atrial Fibrillation, sponsored by AZ Sint-Jan AV.

Who is sponsoring NCT04602169?

NCT04602169 is sponsored by AZ Sint-Jan AV.

What drugs are being tested in NCT04602169?

Interventions in NCT04602169: PVI, PVI + SVC.

What condition does NCT04602169 study?

NCT04602169 studies Paroxysmal Atrial Fibrillation.

Is NCT04602169 still recruiting?

NCT04602169 is currently status unknown. Last updated 3 August 2022.

Last reviewed 2022-08-03 · How we verify

NCT04602169: RECONNECT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Added Value of SVC Isolation in Patients With Pulmonary Vein Reconnection Undergoing Repeat Ablation for Recurrent Paroxysmal AF

Status unknown NA Last updated 3 August 2022

What this trial tests

NA trial testing PVI in Paroxysmal Atrial Fibrillation in 108 participants. Status unknown.

Timeline

16 November 2020

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	AZ Sint-Jan AV
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	108
Start date	16 November 2020
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	1 location across Belgium

Drugs / interventions tested

PVI — full drug profile →
PVI + SVC

Conditions studied

Paroxysmal Atrial Fibrillation — all drugs for Paroxysmal Atrial Fibrillation →

Sponsor

AZ Sint-Jan AV — full company profile →

Who can join

18 and older, any sex, with Paroxysmal Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Redo procedures after CLOSE-guided pulmonary vein isolation (PVI) for atrial fibrillation (AF) occur in 10% of patients. In case of pulmonary vein (PV) reconnection, electrophysiologists may re-isolate the pulmonary veins with or without the ablation of other commonly known PV-triggers. The superior vena cava (SVC) is one of the most common non PV-triggers for atrial tachyarrhythmias. SVC electrical isolation can be reached by circular radiofrequency-ablation under close monitoring of the phrenic nerve. However, it's added value remains unclear. With this prospective, randomized, controlled, unblinded, mono-center study, the investigators aim to evaluate the 1-year recurrence rate in paroxysmal AF patients with reconnected pulmonary veins during a redo ablation with PV re-isolation or PV re-isolation with SVC isolation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PVI

Trials testing the same drug.

NCT07181291 — Pulsed Field or Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation in Heart Failure · completed
NCT07122336 — Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation · NA · recruiting
NCT06705842 — APPI-Cost Trial for Perforated Appendicitis · Phase 4 · recruiting
NCT06825104 — Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation · recruiting
NCT05908955 — Quantitative Superior Vena Cava Isolation in Addition to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation · NA · recruiting

Other recruiting trials for Paroxysmal Atrial Fibrillation

Currently open trials in the same condition.

NCT07535268 — REPRESENT-PF Registry · recruiting
NCT07344961 — Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) · recruiting
NCT07281898 — Burst Stimulation for Paroxysmal Atrial Fibrillation · NA · recruiting
NCT07116525 — A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter · NA · recruiting
NCT06765356 — Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias · Phase 4 · active not recruiting

Other AZ Sint-Jan AV trials

Trials by the same sponsor.

NCT07501481 — Arrhythmic Risk in Myocarditis Outcome Research · not yet recruiting
NCT04784039 — D-Dimer-based Indication for Transesophageal Echocardiography to Exclude Left Atrial Thrombus Before Cardioversion of No · Phase 4 · unknown
NCT06095765 — Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention · Phase 3 · recruiting
NCT05577078 — TriBEL Registry: National Belgian Registry of Percutaneous Tricuspid Valve Repair Using a Transcatheter Edge-to-edge Rep · not yet recruiting
NCT05365568 — Left Bundle Branch Area Pacing Using Conventional Stylet-driven Pacemaker Leads for Cardiac Resynchronization Therapy · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04602169 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AZ Sint-Jan AV
Last refreshed: 3 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04602169.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing